{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T11:07:23Z","timestamp":1749553643235,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41443-021-00430-x","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T09:03:50Z","timestamp":1617786230000},"page":"280-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Trends in treatment of Peyronie\u2019s disease in adult men in the United States from 2008 to 2017\u2014results from an encounter and claims database"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9377-4114","authenticated-orcid":false,"given":"Odinachi I.","family":"Moghalu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupam","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Horns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8697-1531","authenticated-orcid":false,"given":"Alexander","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Hotaling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander W.","family":"Pastuszak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"430_CR1","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(00)05119-9","volume":"357","author":"EW Hauck","year":"2001","unstructured":"Hauck EW, Weidner W. Francois de la Peyronie and the disease named after him. Lancet. 2001;357:2049\u201351.","journal-title":"Lancet."},{"key":"430_CR2","first-page":"129","volume":"9","author":"G Paulis","year":"2017","unstructured":"Paulis G, Paulis A, Romano G, Barletta D, Fabiani A. Rationale of combination therapy with antioxidants in medical management of Peyronie\u2019s disease: results of clinical application. Res Rep Urol. 2017;9:129\u201339.","journal-title":"Res Rep Urol."},{"key":"430_CR3","doi-asserted-by":"publisher","first-page":"4653512","DOI":"10.1155\/2017\/4653512","volume":"2017","author":"G Paulis","year":"2017","unstructured":"Paulis G, Romano G, Paulis L, Barletta D. Recent pathophysiological aspects of Peyronie\u2019s disease: role of free radicals, rationale, and therapeutic implications for antioxidant treatment-literature review. Adv Urol. 2017;2017:4653512.","journal-title":"Adv Urol."},{"key":"430_CR4","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/sj.ijir.3900875","volume":"14","author":"RB Moreland","year":"2002","unstructured":"Moreland RB, Nehra A. Pathophysiology of Peyronie\u2019s disease. Int J Impot Res. 2002;14:406\u201310.","journal-title":"Int J Impot Res."},{"key":"430_CR5","doi-asserted-by":"publisher","first-page":"e0150157","DOI":"10.1371\/journal.pone.0150157","volume":"11","author":"M Stuntz","year":"2016","unstructured":"Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D. The prevalence of Peyronie\u2019s disease in the United States: a population-based study. PLoS ONE. 2016;11:e0150157.","journal-title":"PLoS ONE."},{"key":"430_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jsxm.2018.04.640","volume":"15","author":"AW Pastuszak","year":"2018","unstructured":"Pastuszak AW, Rodriguez KM, Solomon ZJ, Kohn TP, Lipshultz LI, Eisenberg ML. Increased risk of incident disease in men with Peyronie\u2019s disease: analysis of U.S. claims data. J Sex Med. 2018;15:894\u2013901.","journal-title":"J Sex Med."},{"key":"430_CR7","doi-asserted-by":"publisher","first-page":"282503","DOI":"10.1155\/2011\/282503","volume":"2011","author":"DB Dibenedetti","year":"2011","unstructured":"Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie\u2019s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:282503.","journal-title":"Adv Urol."},{"key":"430_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1046\/j.1464-4096.2001.02436.x","volume":"88","author":"U Schwarzer","year":"2001","unstructured":"Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie\u2019s disease: results of a large survey. BJU Int. 2001;88:727\u201330.","journal-title":"BJU Int."},{"key":"430_CR9","unstructured":"Fala L. Xiaflex (collagenase clostridium histolyticum), first drug approved by the FDA for Peyronie\u2019s Disease. American Health & Drug Benefits. 7."},{"key":"430_CR10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","volume":"194","author":"A Nehra","year":"2015","unstructured":"Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie\u2019s disease: AUA guideline. J Urol. 2015;194:745\u201353.","journal-title":"J Urol."},{"key":"430_CR11","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jsxm.2018.01.025","volume":"15","author":"E Chung","year":"2018","unstructured":"Chung E, Wang R, Ralph D, Levine L, Brock G. A worldwide survey on Peyronie\u2019s disease surgical practice patterns among surgeons. J Sex Med. 2018;15:568\u201375.","journal-title":"J Sex Med."},{"key":"430_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s11934-011-0212-2","volume":"12","author":"EC Serefoglu","year":"2011","unstructured":"Serefoglu EC, Hellstrom WJ. Treatment of Peyronie\u2019s disease: 2012 update. Curr Urol Rep. 2011;12:444\u201352.","journal-title":"Curr Urol Rep."},{"key":"430_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1517\/14656566.2011.544252","volume":"12","author":"S Gur","year":"2011","unstructured":"Gur S, Limin M, Hellstrom WJ. Current status and new developments in Peyronie\u2019s disease: medical, minimally invasive and surgical treatment options. Expert Opin Pharmacother. 2011;12:931\u201344.","journal-title":"Expert Opin Pharmacother"},{"key":"430_CR14","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","volume":"7","author":"D Ralph","year":"2010","unstructured":"Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M, et al. The management of Peyronie\u2019s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7:2359\u201374.","journal-title":"J Sex Med."},{"key":"430_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199\u2013207.","journal-title":"J Urol."},{"key":"430_CR16","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","volume":"187","author":"M Gelbard","year":"2012","unstructured":"Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase clostridium histolyticum in patients with Peyronie disease. J Urol 2012;187:2268\u201374.","journal-title":"J Urol"},{"key":"430_CR17","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jsxm.2019.03.404","volume":"16","author":"H Porst","year":"2019","unstructured":"Porst H, Burri A. European Society for Sexual Medicine Educational C. Current strategies in the management of Peyronie\u2019s disease (PD)-results of a survey of 401 sexual medicine experts across Europe. J Sex Med. 2019;16:901\u20138.","journal-title":"J Sex Med"},{"key":"430_CR18","doi-asserted-by":"crossref","unstructured":"Teloken P, Katz D. Medical management of Peyronie\u2019s disease: review of the clinical evidence. Med Sci. 2019;7:96.","DOI":"10.3390\/medsci7090096"},{"key":"430_CR19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/andr.12058","volume":"3","author":"FA Yafi","year":"2015","unstructured":"Yafi FA, Pinsky MR, Sangkum P, Hellstrom WJ. Therapeutic advances in the treatment of Peyronie\u2019s disease. Andrology. 2015;3:650\u201360.","journal-title":"Andrology."},{"key":"430_CR20","unstructured":"Hansen LG, Chang S.\u00a0Health research data for the real world: The marketscan databases [White paper]. Truven Health Analytics. 2011."},{"key":"430_CR21","unstructured":"Butler JQ. Health research data for the real world: The markertScan databases [White paper]. Truven Health Analytics. 2015."},{"key":"430_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5534\/wjmh.180073","volume":"37","author":"AJ Sun","year":"2019","unstructured":"Sun AJ, Li S, Eisenberg ML. The impact of clostridium histolyticum collagenase on the prevalence and management of Peyronie\u2019s disease in the United States. World J Mens Health. 2019;37:234\u20139.","journal-title":"World J Mens Health."},{"key":"430_CR23","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1590\/1806-9282.65.10.1231","volume":"65","author":"G Aita","year":"2019","unstructured":"Aita G, Ros CTD, Silvinato A, Bernardo WM. Peyronie\u2019s disease: clinical treatment. Rev Assoc Med Bras. 2019;65:1231\u20139.","journal-title":"Rev Assoc Med Bras."},{"key":"430_CR24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","volume":"13","author":"E Chung","year":"2016","unstructured":"Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, et al. Evidence-based management guidelines on Peyronie\u2019s disease. J Sex Med. 2016;13:905\u201323.","journal-title":"J Sex Med"},{"key":"430_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00120-015-3796-1","volume":"54","author":"G Hatzichristodoulou","year":"2015","unstructured":"Hatzichristodoulou G. [Conservative therapy of Peyronie\u2019s disease\u2014update 2015]. Urol A. 2015;54:641\u20137.","journal-title":"Urol A."},{"key":"430_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/andr.292","volume":"3","author":"J Sullivan","year":"2015","unstructured":"Sullivan J, Moskovic D, Nelson C, Levine L, Mulhall J. Peyronie\u2019s disease: urologist\u2019s knowledge base and practice patterns. Andrology. 2015;3:260\u20134.","journal-title":"Andrology."},{"key":"430_CR27","first-page":"1","volume":"8","author":"G Paulis","year":"2016","unstructured":"Paulis G, Barletta D, Turchi P, Vitarelli A, Dachille G, Fabiani A, et al. Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie\u2019s disease: a case-control study. Res Rep. Urol. 2016;8:1\u201310.","journal-title":"Res Rep. Urol."},{"key":"430_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0090-4295(94)80155-X","volume":"44","author":"E Akkus","year":"1994","unstructured":"Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie\u2019s disease? A pilot study. Urology. 1994;44:291\u20135.","journal-title":"Urology."},{"key":"430_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","volume":"16","author":"MR Safarinejad","year":"2004","unstructured":"Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie\u2019s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16:238\u201343.","journal-title":"Int J Impot Res."},{"key":"430_CR30","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1046\/j.1464-410X.2003.04134.x","volume":"91","author":"RMP Castro","year":"2003","unstructured":"Castro RMP, Vallejo MEL, Lopez JCR, Curado FJA, Kindelan JA, Tapia MJR. Combined treatment with vitamin E and colchicine in the early stages of Peyronie\u2019s disease. BJU Int. 2003;91:522\u20134.","journal-title":"BJU Int."},{"key":"430_CR31","unstructured":"American Urological Association,\u00a0The State of Urology Workforce and Practice in the United States 2017.\u00a0Linthicum, Maryland, U.S.A., March 9, 2018. Retrieved on March 23, 2020 from https:\/\/www.AUAnet.org\/common\/pdf\/research\/census\/State-Urology-Workforce-Practice-US.pdf."},{"key":"430_CR32","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/j.1743-6109.2008.01081.x","volume":"6","author":"A Muller","year":"2009","unstructured":"Muller A, Mulhall JP. Peyronie\u2019s disease intervention trials: methodological challenges and issues. J Sex Med. 2009;6:848\u201361.","journal-title":"J Sex Med."},{"key":"430_CR33","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","volume":"14","author":"HMT Nguyen","year":"2017","unstructured":"Nguyen HMT, Anaissie J, DeLay KJ, Yafi FA, Sikka SC, Hellstrom WJG. Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute-phase Peyronie\u2019s disease. J Sex Med. 2017;14:1220\u20135.","journal-title":"J Sex Med."},{"key":"430_CR34","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/bju.12565","volume":"113","author":"CC Carson","year":"2014","unstructured":"Carson CC, Levine LA. Outcomes of surgical treatment of Peyronie\u2019s disease. BJU Int. 2014;113:704\u201313.","journal-title":"BJU Int."},{"key":"430_CR35","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/sj.ijir.3901247","volume":"16","author":"A Kadioglu","year":"2004","unstructured":"Kadioglu A, Oktar T, Kandirali E, Kendirci M, Sanli O, Ozsoy C. Incidentally diagnosed Peyronie\u2019s disease in men presenting with erectile dysfunction. Int J Impot Res. 2004;16:540\u20133.","journal-title":"Int J Impot Res."},{"key":"430_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41443-018-0029-3","volume":"30","author":"A Burri","year":"2018","unstructured":"Burri A, Porst H. The relationship between penile deformity, age, psychological bother, and erectile dysfunction in a sample of men with Peyronie\u2019s Disease (PD). Int J Impot Res. 2018;30:171\u20138.","journal-title":"Int J Impot Res."},{"key":"430_CR37","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.urology.2018.06.049","volume":"120","author":"FA Yafi","year":"2018","unstructured":"Yafi FA, Diao L, DeLay KJ, DeYoung L, Talib R, Alzweri L, et al. Multi-institutional prospective analysis of intralesional injection of collagenase clostridium histolyticum, tunical plication, and partial plaque excision and grafting for the management of Peyronie\u2019s disease. Urology. 2018;120:138\u201342.","journal-title":"Urology."},{"key":"430_CR38","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jsxm.2016.02.105","volume":"13","author":"FA Yafi","year":"2016","unstructured":"Yafi FA, Anaissie J, Zurawin J, Sikka SC, Hellstrom WJ. Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie\u2019s Disease. J Sex Med. 2016;13:684\u20139.","journal-title":"J Sex Med."},{"key":"430_CR39","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.sxmr.2019.05.001","volume":"7","author":"A Amighi","year":"2019","unstructured":"Amighi A, Eleswarapu SV, Mendhiratta N, Nork JJ, Mills JN. Discontinuation from collagenase clostridium histolyticum therapy for Peyronie\u2019s disease: review and single-center cohort analysis. Sex Med Rev. 2019;7:690\u20138.","journal-title":"Sex Med Rev."},{"key":"430_CR40","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1111\/jsm.13072","volume":"12","author":"FA Yafi","year":"2015","unstructured":"Yafi FA, Hatzichristodoulou G, Knoedler CJ, Trost LW, Sikka SC, Hellstrom WJ. Comparative analysis of tunical plication vs. intralesional injection therapy for ventral Peyronie\u2019s disease. J Sex Med. 2015;12:2492\u20138.","journal-title":"J Sex Med"},{"key":"430_CR41","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.juro.2015.03.092","volume":"194","author":"FA Yafi","year":"2015","unstructured":"Yafi FA, Pinsky MR, Stewart C, Sangkum P, Ates E, Trost LW, et al. The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie\u2019s disease. J Urol. 2015;194:754\u20138.","journal-title":"J Urol."},{"key":"430_CR42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","volume":"100","author":"J Anaissie","year":"2017","unstructured":"Anaissie J, Yafi FA, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJG. Impact of number of cycles of collagenase clostridium histolyticum on outcomes in patients with Peyronie\u2019s disease. Urology 2017;100:125\u201330.","journal-title":"Urology"},{"key":"430_CR43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.urology.2016.01.032","volume":"91","author":"FA Yafi","year":"2016","unstructured":"Yafi FA, Hatzichristodoulou G, Wang J, Anaissie J, Sikka SC, Hellstrom WJ. Outcomes of surgical management of men with Peyronie\u2019s disease with hourglass deformity. Urology. 2016;91:119\u201323.","journal-title":"Urology."},{"key":"430_CR44","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.sxmr.2018.09.007","volume":"7","author":"SC Brimley","year":"2019","unstructured":"Brimley SC, Yafi FA, Greenberg J, Hellstrom WJG, Tue Nguyen HM, Hatzichristodoulou G. Review of management options for active-phase Peyronie\u2019s disease. Sex Med Rev. 2019;7:329\u201337.","journal-title":"Sex Med Rev."}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-021-00430-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-021-00430-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-021-00430-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T18:03:12Z","timestamp":1650823392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-021-00430-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1038\/s41443-021-00430-x","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"type":"print","value":"0955-9930"},{"type":"electronic","value":"1476-5489"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"8 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AWP declares the following conflict(s) of interest: (1) Endo Pharmaceuticals\u2014advisor, consultant, speaker, research support, fellowship support. (2) Antares Pharmaceuticals\u2014advisor. (3) Bayer AG\u2014speaker. (4) Inherent Biosciences \u2013 advisor. (5) Allotrope Medical\u2014advisor. (6) Woven Health\u2014founder and leadership role. (7) Vault Health\u2014leadership role. JMH declares the following conflict(s) of interest: (1) Endo pharmaceuticals\u2014educational and research grants. (2) Boston Scientific\u2014educational grants. (3) StreamDx, Nanonc, Andro360\u2014founder\/own equity (early-stage startups). (4) Inherent Biosciences\u2014own equity. (5) Turtle Health\u2014advisor. OIM, RD, JH, and AC have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}